Avalo Therapeutics, Inc. (AVTX)
18.95
-0.39
(-2.02%)
USD |
NASDAQ |
Sep 01, 16:00
18.97
+0.02
(+0.11%)
After-Hours: 20:00
Avalo Therapeutics Cash from Investing (Quarterly) : -329.92M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -329.92M |
| March 31, 2026 | 25.50M |
| December 31, 2025 | 2.401M |
| September 30, 2025 | -13.26M |
| June 30, 2025 | -70.86M |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.356M |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | -0.133M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | -0.039M |
| June 30, 2022 | -0.056M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | -0.011M |
| September 30, 2021 | -0.081M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | -0.021M |
| December 31, 2020 | -0.3912M |
| September 30, 2020 | -0.0627M |
| June 30, 2020 | 12.84M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.251M |
| December 31, 2019 | |
| September 30, 2019 | -0.0051M |
| June 30, 2019 | -0.091M |
| March 31, 2019 | -0.166M |
| December 31, 2018 | -0.4994M |
| September 30, 2018 | 1.391M |
| June 30, 2018 | -0.0067M |
| March 31, 2018 | -0.0192M |
| December 31, 2017 | -18.90M |
| September 30, 2017 | -0.0062M |
| June 30, 2017 | 0.00 |
| March 31, 2017 | -0.0018M |
| December 31, 2016 | -0.0092M |
| September 30, 2016 | -0.0065M |
| June 30, 2016 | -0.0103M |
| March 31, 2016 | -0.0089M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | -0.02M |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Incyte Corp. | -51.79M |
| AbbVie, Inc. | -1.197B |
| Rezolute, Inc. | 12.28M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.99M |
| Cash from Financing (Quarterly) | 410.21M |
| Free Cash Flow | -68.29M |
| Free Cash Flow Per Share (Quarterly) | -0.4584 |
| Free Cash Flow to Equity (Quarterly) | -19.90M |
| Free Cash Flow to Firm (Quarterly) | -19.99M |
| Free Cash Flow Yield | -14.98% |